You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Index 301<br />
peptidosulfonamide, disadvantage<br />
of, 227<br />
schematic representation of, 225<br />
Peptidosulfonamides<br />
assembly of, methods for, 226<br />
peptidomimetics, disadvantage of, 227<br />
synthesis of, 223–225<br />
solid-phase, 230<br />
Peptoids<br />
assembly of, methods for, 226<br />
peptide-peptoid hybrid synthesis and, 238<br />
polymer class represented by, 238<br />
sequencing of, 240<br />
synthesis of, 223<br />
methods for, 239<br />
Peptomers<br />
assembly of, methods for, 226<br />
sequencing of, 240<br />
synthesis of, 224<br />
Pharmacokinetics, 182<br />
Phosphoamino acids<br />
direct incorporation of derivatives of Fmoc, 211<br />
partially protected, 211<br />
Phosphonopeptides<br />
assembly of, methods for, 226<br />
synthesis of, 223<br />
Phosphopeptides<br />
as cocrystallized, 217<br />
disease-specific changes influenced by, 209<br />
methods for synthesis by Fmoc chemistry<br />
of, 214<br />
MS and, 216, 219<br />
O-, solid phase synthesis of, 209–217<br />
synthesis of, 214<br />
synthetic, analysis of, 216<br />
Phosphorylation<br />
global, 215<br />
of hydroxyl groups, 209<br />
of partially protected peptides, 212<br />
Phosphothreonine, 214<br />
Phosphotyrosine, 214<br />
Photo-induced cross-linking of unmodified proteins<br />
(PICUP) assays, method, 74<br />
PICUP assays. See Photo-induced cross-linking of<br />
unmodified proteins assays<br />
Plasmids, 171, 277–279<br />
See Projections to latent structures<br />
Polypeptides, 276–277<br />
Polypropylene rod, peptides bound to, 57<br />
Principal component analysis (PCA), 136<br />
Projections to latent structures (PLS), 136<br />
Proline-rich antimicrobial peptides (PRPs)<br />
biological membranes as crossed by, 162<br />
characteristics of, 161–162<br />
E. coli mutants resistant to, 165–166, 169<br />
genomic DNA libraries and, 166<br />
mode of action of, 161–171<br />
molecular interactions of, methods for<br />
identifying, 165–173<br />
resistance, 163–164, 167–169, 171<br />
characterization of, 164<br />
resistant mutant clones, 164–165<br />
characterization of, 167<br />
resistant mutant clones’ degree of<br />
resistance, 167<br />
ProteinChip technology<br />
arrays, 73–74, 76–80<br />
A� capture and quantitation using<br />
antibody-coated arrays of, 76–80<br />
A� interactions analysis using, 71–83<br />
method of, 73<br />
Proteins. See also Amyloid precursor protein;<br />
Glycoproteins; Major histocompatibility<br />
complex proteins<br />
AP-labeled, 50, 63<br />
biotin labeling of samples of, 50, 63–64<br />
chemical shifts for, 95<br />
chemiluminescence and, 50<br />
Cys-tagged, 276–285<br />
site-specific conjugation to, 279–280<br />
drugs in human disease treatment, 10<br />
expression, 285–286<br />
fusion Cys-tag for site-specific modification of<br />
targeting, 276–277<br />
glycosylation of, 189<br />
HRP-labeled, 50, 63<br />
imaging/therapeutic agents coupled to,<br />
276–277<br />
M2, 263<br />
mammalian, 209<br />
modifications via novel Cys-tag of, 276<br />
native, 264<br />
producing, 263<br />
peptide interactions with, 47<br />
protein conjugation, 285, 289–290<br />
purification, 285–287<br />
site-specifically biotinylated Cys-tagged,<br />
282–283<br />
staining and, 63<br />
targeted, 162<br />
targeted into liposomes, lipidation for insertion<br />
of, 286<br />
therapeutics, 185<br />
transport, 162<br />
use of Cys-tagged, 280–282<br />
PRPs. See Proline-rich antimicrobial peptides